HIV-1 Infection – Pipeline Review, H1 2013Global Markets DirectFebruary 28, 2013 193 Pages - SKU: GMD4986606 |
- Introduction
- Global Markets Direct Report Coverage
- HIV-1 Infection Overview
- Therapeutics Development
- An Overview of Pipeline Products for HIV-1 Infection
- HIV-1 Infection Therapeutics under Development by Companies
- HIV-1 Infection Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- HIV-1 Infection Therapeutics – Products under Development by Companies
- HIV-1 Infection Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in HIV-1 Infection Therapeutics Development
- Bristol-Myers Squibb Company
- Johnson & Johnson
- GlaxoSmithKline plc
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- United Biomedical, Inc.
- Aphios Corporation
- Pfizer Inc.
- Avexa Limited
- Koronis Pharmaceuticals, Inc.
- Alfacell Corporation
- Geron Corporation
- GeoVax Labs, Inc.
- Enzo Biochem, Inc.
- ConjuChem Biotechnologies Inc.
- Critical Outcome Technologies Inc.
- Takara Bio Inc.
- Functional Genetics, Inc.
- BioClonetics Incorporated
- Nutri Pharma ASA
- Vironova AB
- ViroStatics, srl
- Argos Therapeutics, Inc.
- Proteologics, Inc.
- GeneCure LLC
- Tobira Therapeutics, Inc.
- Medestea Research & Production S.p.A.
- ViiV Healthcare
- Spider Biotech S.r.l.
- RFS Pharma, LLC
- Prosetta Corporation
- Vichem Chemie Research Ltd.
- AltraVax Inc.
- HIV-1 Infection – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- pGA2/JS7 DNA Vaccine + Recombinant Modified Vaccinia Ankara/HIV62B Vaccine - Drug Profile
- amdoxovir - Drug Profile
- cenicriviroc mesylate - Drug Profile
- AGS-004 - Drug Profile
- apricitabine - Drug Profile
- dapivirine - Drug Profile
- HGTV-43 - Drug Profile
- lovastatin - Drug Profile
- (didanosine + hydroxyurea) - Drug Profile
- human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant - Drug Profile
- MVA.HIVA Vaccine - Drug Profile
- VRC-HIVADV014-00-VP - Drug Profile
- VRC-HIVDNA009-00-VP - Drug Profile
- Vacc-4x - Drug Profile
- BMS-663068 - Drug Profile
- TMC-310911 - Drug Profile
- KP-1461 - Drug Profile
- EP HIV-1043 + EP HIV-1090 - Drug Profile
- EP HIV-1090 - Drug Profile
- Recombinant HIV-1 Tat Protein - Drug Profile
- Ad5.ENVA.48 HIV-1 vaccine - Drug Profile
- MVA.HIVconsv - Drug Profile
- Recombinant Adenovirus Serotype 5 Env A - Drug Profile
- tenofovir alafenamide - Drug Profile
- MK-0518 + [efavirenz] + [lamivudine] + [tenofovir] - Drug Profile
- KD-247 - Drug Profile
- HIV-1 Integrase Inhibitors - Drug Profile
- aldesleukin + CD-4 Zeta Gene-Modified T Cells - Drug Profile
- UB-421 - Drug Profile
- Drug for HIV-1 - Drug Profile
- GRN-665 - Drug Profile
- lersivirine + [emtricitabine] + [tenofovir disoproxil fumarate] - Drug Profile
- Drug For HIV - Drug Profile
- GSK Biologicals HIV Vaccine 732462 - Drug Profile
- APH-0812 - Drug Profile
- Reyataz + Cobicistat - Drug Profile
- Cobicistat + Prezista - Drug Profile
- HIV-1 Therapeutic Vaccine - Drug Profile
- Leukothera - Drug Profile
- Vacc-4x + [lenalidomide] - Drug Profile
- PF-46396 - Drug Profile
- rAmphinase-2 - Drug Profile
- Replication-defective HIV-1 vaccine - Drug Profile
- lersivirine + [darunavir] + [ritonavir] - Drug Profile
- MK-1439 - Drug Profile
- CDK-9 Inhibitors - Drug Profile
- MazF-Based HIV-1 Gene Therapy - Drug Profile
- AFO-18–CAF01 Vaccine - Drug Profile
- FGI-111 - Drug Profile
- CLONE-3 - Drug Profile
- Atazanavir + Lamivudine + Ritonavir - Drug Profile
- AT-96 - Drug Profile
- SB-105 - Drug Profile
- VRC-01 - Drug Profile
- PAV-8802 Series - Drug Profile
- HIV-1 Program - Drug Profile
- GS-8374 - Drug Profile
- HIV-1 Vaccine - Drug Profile
- Calanolide B - Drug Profile
- DS-003 - Drug Profile
- DS-001 - Drug Profile
- M48-U1 - Drug Profile
- HIV-1 Protease Inhibitors - Drug Profile
- Ank(GAG)1D4 - Drug Profile
- PNA-Neamine Conjugate - Drug Profile
- HIV-1 Latency Reversing Agents - Drug Profile
- HIV-1 Infection Therapeutics – Drug Profile Updates
- HIV-1 Infection Therapeutics – Discontinued Products
- HIV-1 Infection Therapeutics - Dormant Products
- HIV-1 Infection – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for HIV-1 Infection, H1 2013
- Products under Development for HIV-1 Infection – Comparative Analysis, H1 2013
- Number of Products under Development by Companies, H1 2013
- Number of Products under Development by Companies, H1 2013 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, H1 2013
- Comparative Analysis by Late Stage Development, H1 2013
- Comparative Analysis by Mid Clinical Stage Development, H1 2013
- Comparative Analysis by Early Clinical Stage Development, H1 2013
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
- Products under Development by Companies, H1 2013
- Products under Development by Companies, H1 2013 (Contd..1)
- Products under Development by Companies, H1 2013 (Contd..2)
- Products under Investigation by Universities/Institutes, H1 2013
- Products under Investigation by Universities/Institutes, H1 2013 (Contd..1)
- Bristol-Myers Squibb Company, H1 2013
- Johnson & Johnson, H1 2013
- GlaxoSmithKline plc, H1 2013
- Gilead Sciences, Inc., H1 2013
- Merck & Co., Inc., H1 2013
- United Biomedical, Inc., H1 2013
- Aphios Corporation, H1 2013
- Pfizer Inc., H1 2013
- Avexa Limited, H1 2013
- Koronis Pharmaceuticals, Inc., H1 2013
- Alfacell Corporation, H1 2013
- Geron Corporation, H1 2013
- GeoVax Labs, Inc., H1 2013
- Enzo Biochem, Inc., H1 2013
- ConjuChem Biotechnologies Inc., H1 2013
- Critical Outcome Technologies Inc., H1 2013
- Takara Bio Inc., H1 2013
- Functional Genetics, Inc., H1 2013
- BioClonetics Incorporated, H1 2013
- Nutri Pharma ASA, H1 2013
- Vironova AB, H1 2013
- ViroStatics, srl, H1 2013
- Argos Therapeutics, Inc., H1 2013
- Proteologics, Inc., H1 2013
- GeneCure LLC, H1 2013
- Tobira Therapeutics, Inc., H1 2013
- Medestea Research & Production S.p.A., H1 2013
- ViiV Healthcare, H1 2013
- Spider Biotech S.r.l., H1 2013
- RFS Pharma, LLC, H1 2013
- Prosetta Corporation, H1 2013
- Vichem Chemie Research Ltd., H1 2013
- AltraVax Inc., H1 2013
- Assessment by Monotherapy Products, H1 2013
- Assessment by Combination Products, H1 2013
- Assessment by Stage and Route of Administration, H1 2013
- Assessment by Stage and Molecule Type, H1 2013
- HIV-1 Infection Therapeutics – Drug Profile Updates
- HIV-1 Infection Therapeutics – Discontinued Products
- HIV-1 Infection Therapeutics – Dormant Products
- HIV-1 Infection Therapeutics – Dormant Products (Contd..1)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..2)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..3)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..4)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..5)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..6)
- List of Figures
- Number of Products under Development for HIV-1 Infection, H1 2013
- Products under Development for HIV-1 Infection – Comparative Analysis, H1 2013
- Products under Development by Companies, H1 2013
- Products under Investigation by Universities/Institutes, H1 2013
- Late Stage Products, H1 2013
- Mid Clinical Stage Products, H1 2013
- Early Clinical Stage Products, H1 2013
- Discovery and Pre-Clinical Stage Products, H1 2013
- Assessment by Monotherapy Products, H1 2013
- Assessment by Combination Products, H1 2013
- Assessment by Route of Administration, H1 2013
- Assessment by Stage and Route of Administration, H1 2013
- Assessment by Molecule Type, H1 2013
- Assessment by Stage and Molecule Type, H1 2013
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Drug Discovery Reports